

Filed January 29, 2026

On behalf of **Dr. Falk Pharma GmbH**

By: Nathanael R. Luman (Reg. No. 63,160)
Eric S. Furman (Reg. No. 45,664)
Phillip J. Minnick (Reg. No. 81,223)
KNOBBE, MARTENS, OLSON & BEAR, LLP
3579 Valley Centre Drive, Suite 300
San Diego, CA 92130
Tel.: (949) 760-0404
Fax: (949) 760-9502
Email: BoxFalkPharma@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner,

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner.

PGR2025-00086
Patent No. 12,290,598

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to the Board’s email of January 29, 2026 (EX3103) authorizing Petitioner Dr. Falk Pharma GmbH to file Adverse Judgments against Patent Owner in the related matters of IPR2025-00052, -00054, -00055, and -00056 as exhibits in this proceeding, Petitioner filed the Adverse Judgments as Exhibits 1138-1141 in this proceeding and provides this updated exhibit list under 37 C.F.R. § 42.63(e).

Exhibit No.	Description
1001	U.S. Patent No. 12,290,598 to Perrett et al.
1002	U.S. Publication No. 20070111978 to Dohil et al.
1003	RESERVED
1004	The Opposition Division of the European Patent Office decision revoking EP2484822B1 with auxiliary requested claims
1005	“Guidance for Industry: Orally Disintegrating Tablets,” U.S. Food & Drug Administration, Center for Drug Evaluation and Research (CDER), 2008.
1006	RESERVED
1007	“DRAFT Guidance for Industry: Orally Disintegrating Tablets,” U.S. Food & Drug Administration, Center for Drug Evaluation and Research (CDER), 2007.
1008	International Publication No. WO2000044351 to Grother et al.
1009	Svoboda et al., “Oral formulations of budesonide: a novel treatment for inflammatory bowel disease,” <i>Drugs of Today</i> , 44:857-863 (2008) at 857.
1010	Tan et al., “Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets,” <i>European Journal of Gastroenterology & Hepatology</i> , 13:425-427 (2001)

Exhibit No.	Description
1011	Kolkman et al., “Evaluation of oral budesonide in the treatment of active distal ulcerative colitis,” <i>Drugs of Today</i> , 40:589-601 (2004)
1012	Siewert et al., “Eosinophilic gastroenteritis with severe protein-losing enteropathy: Successful treatment with budesonide,” <i>Digestive and Liver Disease</i> , 38:55-59 (2006)
1013	Elsing et al., “Budesonide for the treatment of obstructive eosinophilic jejunitis,” <i>Z. Gastroenterology</i> , 45:187-189 (2007).
1014	Aceves et al., “Topical viscous budesonide suspension for treatment of eosinophilic esophagitis,” <i>Journal of Allergy and Clinical Immunology</i> 116:705-706 (2005)
1015	Aceves et al., “Oral Viscous Budesonide: A potential new therapy for eosinophilic esophagitis in children,” <i>American Journal of Gastroenterology</i> , 102:1-9 (2007)
1016	RESERVED
1017	Danckwerts, “Intraoral Drug Delivery: A Comparative Review,” <i>American Journal of Drug Delivery</i> , 1:171-186 (2003).
1018	Fu et al., “Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies,” <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 21:433-475 (2004)
1019	Shukla et al., “Mouth Dissolving Tablets I: An overview of formulation technology,” <i>Scientia Pharmaceutica</i> , 77:309-326 (2009) (March 6, 2009)
1020	U.S. Publication No. 20050232988 to Venkatesh et al. (“Venkatesh988”)
1021-1024	RESERVED
1025	Goodman & Gilman’s: <i>The Pharmacological Basis of Therapeutics</i> , 11th edition, eds. Brunton, Lazo, Parker, 2005
1026	Budenofalk® Brochure (2005)

Exhibit No.	Description
1027	Budenofalk® Advertisement (2007)
1028	Dr. Falk Pharma Brochure (2008)
1029	<i>Curriculum Vitae</i> of Alan F. Parr, Pharm.D., Ph.D.
1030	RESERVED
1031	Prosecution history excerpts from U.S. Application No.12/896,005
1032	RESERVED
1033	Teitelbaum et al., Eosinophilic esophagitis in children: Immunopathological analysis and response to fluticasone propionate,” <i>Gastroenterology</i> 122:1216-1225 (2002)
1034	Noel et al., “Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis,” <i>Clinical Gastroenterology and Hepatology</i> 2:568-575 (2004)
1035	U.S. Patent No. 7,122,198 to Singh et al.
1036	U.S. Patent No. 7,229,641 Cherukuri et al.
1037-1039	RESERVED
1040	USP Convention 701 Disintegration, Revision Bulletin August 1, 2008
1041	Conway, “Solid dosage forms,” Chapter 4.1 in <i>Pharmaceutical Manufacturing Handbook: Production and Processes</i> , ed. Gad, pages 235-265 (2008)
1042-1046	RESERVED
1047	El-Arini et al., “Evaluation of disintegration testing of different fast dissolving tablets using the texture analyzer,” <i>Pharmaceutical Development & Technology</i> , 7:361-371 (2002)
1048-1063	RESERVED

Exhibit No.	Description
1064	Roeder et al., “Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases,” <i>Skin Pharmacology Physiology</i> , 18:3-11 (2004)
1065	Remedios et al., “Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate,” <i>Gastrointestinal Endoscopy</i> , 63:3-12 (2006)
1066	Konikoff et al., “A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis,” <i>Gastroenterology</i> , 131:1381-1391 (2006)
1067-1094	RESERVED
1095	Declaration of Alan F. Parr, Pharm.D., Ph.D. supporting PGR petition of U.S. 12,290,598
1096	Prosecution history excerpts from U.S. Application No. 17/569,047, which issued as U.S. 12,290,598
1097	U.S. Application No. 17/569,047 as filed on January 5, 2022 (“the ’047 Application”)
1098	U.S. Application No. 16/821,464 as filed on March 17, 2020 (“the ’464 Application”)
1099	U.S. Application No. 15/816,154 as filed on November 17, 2017 (“the ’154 Application”)
1100	U.S. Application No. 15/205,390 as filed on July 8, 2016 (“the ’390 Application”)
1101	U.S. Application No. 14/311,732 as filed on June 23, 2014 (“the ’732 Application”)
1102	U.S. Application No. 12/896,005 as filed on October 1, 2010 (“the ’005 Application”)
1103	U.S. Provisional Application No. 61/247,642 as filed on October 1, 2009 (“the ’642 Application”)

Exhibit No.	Description
1104	The United States Pharmacopeia, USP 31, 2008 (“USP”)
1105	The European Pharmacopeia, 6.0, 2008
1106	Remington: The science and practice of pharmacy, 20th edition, pages 882-884 (2000).
1107	Lee, “Pharmaceutical Preformulation,” in Pharmaceutical Manufacturing Handbook: Production and Processes, pages 881-931 (2008).
1108	Seitz et al., “Evaluation of the physical properties of compressed tablets I,” Journal of Pharmaceutical Sciences, 54:1353-1357 (1965)
1109	U.S. Patent No. 8,771,729 to Perrett et al.
1110	International Publication No. WO2002015884 to Kararli et al. (“Kararli”)
1111	International Publication No. WO2009006516 to Venkatesh et al. (“Venkatesh516”)
1112	International Publication No. WO2010127345 to Venkatesh et al. (“Venkatesh345”)
1113	International Publication No. WO2010127346 to Venkatesh et al. (“Venkatesh346”)
1114-1116	RESERVED
1117	Petitioner’s Reply Brief, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2024-01197, Paper 20
1118	Judgment Granting Request for Adverse Judgment after Institution of Trial, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2024-01197, Paper 41 (PTAB 2025)
1119	2024-10-23 Transcript of Oral Hearing Dismissing Complaint, <i>Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma</i> , Case No. 24-cv-01392-PTG (E.D. Va)

Exhibit No.	Description
1120	Judgment Against Ellodi in <i>Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH</i> , Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Original German Language
1121	Judgment Against Ellodi in <i>Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH</i> , Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Certified English Language Translation
1122-1128	RESERVED
1129	PTAB email instructing Ellodi Pharmaceuticals that declaration evidence may not be submitted with Patent Owner’s Sur-reply, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2024-01197, EX3003
1130	Email exchange between PTAB and Ellodi Pharmaceuticals regarding improper exhibits submitted with Patent Owner’s Sur-reply, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> IPR2024-01197, EX3004
1131	Patent Owner’s Opposition To Petitioner’s Motion For Additional Discovery, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00052, Paper 22
1132	Patent Owner’s Opposition To Petitioner’s Motion For Additional Discovery, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00054, Paper 23
1133	Email exchange between PTAB and the Parties regarding additional discovery and false statement in Patent Owner Opposition brief, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00052 and IPR2025-00054, EX3001
1134	Petitioner’s email to the Director regarding Patent Owner’s unauthorized request for Certificate of Correction, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , PGR2025-00086
1135	Patent Owner’s Response, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00052, Paper 15

Exhibit No.	Description
1136	Patent Owner’s Response, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00054, Paper 16
1137	Patent Owner’s Response, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00055, Paper 15
1138	Judgment Granting Request for Adverse Judgment after Institution of Trial, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00052, Paper 33 (PTAB 2026)
1139	Judgment Granting Request for Adverse Judgment after Institution of Trial, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00054, Paper 34 (PTAB 2026)
1140	Judgment Granting Request for Adverse Judgment after Institution of Trial, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00055, Paper 31 (PTAB 2026)
1141	Judgment Granting Request for Adverse Judgment after Institution of Trial, <i>Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.</i> , IPR2025-00056, Paper 25 (PTAB 2026)

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 29, 2026 /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)

Eric S. Furman (Reg. No. 45,664)

Phillip J. Minnick (Reg. No. 81,223)

Counsel for Petitioner

Dr. Falk Pharma GmbH

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on the date below a copy of
PETITIONER’S UPDATED EXHIBIT LIST AND EXHIBIT NOS. 1138-1141
were served by email to counsel for Ellodi at the addresses below:

Sanya Sukduang
ssukduang@cooley.com

Jonathan Cousin
jcousin@cooley.com

Isha Agarwal
iagarwal@cooley.com

Ellodi_IPR@cooley.com

Dated: January 29, 2026

/Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP

Counsel for Petitioner
Dr. Falk Pharma GmbH